Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value

$10.99−0.21 (-1.87%)

Close on Nov 13, 2026Market cap $320.09MP/E –Yield –

Enanta Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Enanta Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Enanta Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENTA.

Operating margin-90.0% · median -74.9%

Net margin-96.9% · median -20.9%

Advertisement
300 × 250

See a number that looks wrong?